Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
LUCENT-1 and -2: Extended induction response with mirikizumab over time in UC
book_2
Source:
ECCO 2024 - Poster session
calendar_today
Published on Medfyle:
March 2024
In this medfyle
Not all patients respond to induction by Week 12, but extended induction could give incremental improvements over time in early non-responders. New data from LUCENT look at extended induction across a range of clinical and symptomatic outcomes.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Medfyle. All rights reserved.
Source: Rubin DT, Charabaty A, Jairath V, et al. P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials. J Crohns Colitis 2024;18(suppl1):jjad212.1031 [P901]
The information and data provided is for information purposes only.
The author(s) of the original article had no involvement in the creation of this content.
